Opexa is a publicly traded business. Let's not forget that it exists to generate a profit and huge financial returns for folks who own the stock.
In order to assure the viability of their product they have to follow a protocol that is acceptable to the government for conducting the trials. These protocols are designed to serve the purpose of satisfying the government, not the participants.
The publicly traded company cannot earn a profit unless it gets approval from the governemnt. Logically, trial participants come in third at best. The effort is foremost designed to meet the needs of the investors and the government.
I don't mean to sound callous, but I know I do.
It's an amazing thing to think of a process that is designed to purposefully give some folks a fake treatment. I also understand the reality of the world and I know this is all accepted practice.
So while I do think it's a great thing that Opexa is working on this, and I'm happy that they might actualy have something that seems to be working for some folks, and I pray every day that we get a cure ......... I don't want to confuse those efforts with the underlying goal. Opexa is not a charitable nonprofit organization.
Regarding funding, money is largely driven by greed in the capital markets that Opexa is now operating in. The fact is that they need to approach prospecive investors with "the cure to MS" and try to convince them that they might double, triple, quaduple their money or more in a short period of time. Opexa did not manage it's money well and hence they are now short of completing the trial and they are looking for money to keep it going. I think they have a good pitch to make, I'm not reading about folks having more exaserbations while on Tovaxin. Hopefully they get the money they need, hopefully the management of the trial is going better than the management of the company. Ken
It would be really nice to be able to put links in here
If I have included a bad link, google the word "Scholar", click link for "Google Scholar". Search for the name of the paper and author in Google Scholar.